Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients with Atrial Cardiopathy, The ARCADIA Randomized Clinical Trial
JAMA 331:573-581, Kamel,H.,et al, 2024
Practice Advisory Update Summary: Patent Foramen Ovale and Secondary Stroke Prevention
Neurol 94:876-885, Messe, S.R.,et al, 2020
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source
NEJM 380:1906-1917, Diener, H.C.,et al, 2019
Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source
NEJM 378:2191-2201, Hart, R.G.,et al, 2018
Aspirin for Acute Stroke of Unknown Etiology in Resourse-Limited Settings
Neurol 83:787-793, Berkowitz, A.L.,et al, 2014
Patent Foramen Ovale Closure and Medical Treatments for Secondary Stroke Prevention
Stroke 43:422-431, Kitsios,G.D.,et al, 2012
Age As a Determinant of Adverse Events in Medically Treated Cryptogenic Stroke Patients with Patent Foramen Ovale
Stroke 35:2145, Homma,S.,et al, 2004